Argent Biopharma Narrows Half-Year Loss as Revenue Jumps but Going Concern Risks Flagged

Argent Biopharma ( (AU:RGT) ) has provided an announcement.

Argent Biopharma reported interim revenue of $171,499 for the half year to 31 December 2025, a sharp rise from $4,283 a year earlier, while cutting its net loss attributable to members to $2.94 million from $12.16 million. The company did not declare any dividends and continues to carry negative net tangible assets per share of 0.1 cents, underlining its early-stage profile and limited balance sheet strength.

During the period, Argent liquidated its Slovenian subsidiary, Argent BioPharma d.o.o., booking a statutory loss on liquidation of $55,395 as part of a strategic decision to exit that operation. The interim accounts were reviewed without a modified audit opinion but included an emphasis of matter around going concern, signaling ongoing uncertainty about the group’s ability to sustain operations without additional support or improved performance.

The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent Biopharma Ltd is a biotechnology company operating through subsidiaries in the United Kingdom, Slovenia and Malta, reporting under International Financial Reporting Standards. The group focuses on biopharmaceutical activities, though it remains loss-making and has net tangible assets per share in negative territory, highlighting ongoing financial pressure and dependence on future funding and operational progress.

Average Trading Volume: 184,673

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.78M

See more data about RGT stock on TipRanks’ Stock Analysis page.